Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption

Journal of Hypertension

Volumn 32, Issue 11, 2014, Pages 2199-2210

  Grisk, Olaf ^a   Koenen, Anna ^a   Meissner, Thomas ^a   Donner, Alexander ^a   Braun, Diana ^a   Steinbach, Antje ^a   Glöckl, Gunnar ^a   Zimmermann, Uwe ^a   Evert, Katja ^a   Evert, Matthias ^a   Katsari, Elpiniki ^b   Löhn, Matthias ^c   Plettenburg, Oliver ^c   Rettig, Rainer ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Heart and Diabetes Center Mecklenburg Vorpommern   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Blood vessels; Humans; Kidney; Rats; Rho kinase; Tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

LITHIUM ION; RHO KINASE; RHO KINASE INHIBITOR; SAR 407899; SODIUM; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SODIUM INTAKE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EQUIPMENT; CONTROLLED STUDY; EXPERIMENTAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY TUBULE ABSORPTION; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SODIUM BALANCE; SODIUM EXCRETION; SUNITINIB INDUCED HYPERTENSION; TELEMETRY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; HYPERTENSION; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; SODIUM INTAKE; VASCULAR RESISTANCE; VASCULARIZATION; VASODILATATION;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ARTERIAL PRESSURE; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; INDOLES; KIDNEY TUBULES; MALE; MIDDLE AGED; PYRROLES; RATS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RHO-ASSOCIATED KINASES; SODIUM; SODIUM, DIETARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR RESISTANCE; VASODILATION;

EID: 84927616080     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000326     Document Type: Article

References (51)

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
2. Woolard J, Bevan HS, Harper SJ, Bates DO. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 2009; 16:572-592.
3. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008; 15:715-738.
4. Wei W, Jin H, Chen ZW, Zioncheck TF, Yim AP, He GW. Vascular endothelial growth factor-induced nitric oxide-and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 2004; 44:615-621.
5. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010; 36:416-424.
6. Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 2009; 27:2297-2309.
7. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:763-773.
8. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27:6152-6159.
9. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10:151-156.
10. Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, et al. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 2012; 109:11306-11311.
11. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, Firvida-Perez JL, Vazquez-Estevez S, Lazaro-Quintela M, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011; 22:1-8.
12. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59:151-157.
13. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58:295-302.
14. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56:675-681.
15. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54:652-658.
16. Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, Mazzone M, Vanhoutte G, et al. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation 2010; 122:273-281.
17. Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Molec Biol 2011; 45:804-808.
18. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009; 157:258-270.
19. Srivastava AK, St-Louis J. Smooth muscle contractility and protein tyrosine phosphorylation. Mol Cell Biochem 1997; 176:47-51.
20. Guyton AC. The surprising kidney-fluid mechanism for pressure control-its infinite gain!. Hypertension 1990; 16:725-730.
21. Rettig R, Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension 2005; 46:463-468.
22. Gu JW, Manning RD Jr, Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 2009; 297:R142-R148.
23. Grisk O. Potential benefits of Rho-kinase inhibition in arterial hypertension. Curr Hypertens Rep 2013; 15:506-513.
24. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010; 1802:1276-1284.
25. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009; 54:676-683.
26. Grisk O, Schluter T, Reimer N, Zimmermann U, Katsari E, Plettenburg O, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens 2012; 30:980-989.
27. Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, Klemke R. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010; 123:2332-2341.
28. Ueno K, Hirata H, Shahryari V, Chen Y, Zaman MS, Singh K, et al. Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer 2011; 104:308-315.
29. Schluter T, Zimmermann U, Protzel C, Miehe B, Klebingat KJ, Rettig R, Grisk O. Intrarenal artery superoxide is mainly NADPH oxidasederived and modulates endothelium-dependent dilation in elderly patients. Cardiovasc Res 2010; 85:814-824.
30. Schluter T, Rohsius R, Wanka H, Schmid C, Siepelmeyer A, Rettig R, et al. Amiloride lowers arterial pressure in cyp1a1ren-2 transgenic rats without affecting renal vascular function. J Hypertens 2010; 28:2267-2277.
31. Mahler N, Freyer M, Kauschke R, Schluter T, Steinbach AC, Oswald S, et al. Kidney-specific deletion of multidrug resistance-related protein 2 does not aggravate acute cyclosporine A nephrotoxicity in rats. Pharmacogenet Genomics 2012; 22:408-420.
32. Grisk O, Heukaufer M, Steinbach A, Gruska S, Rettig R. Analysis of arterial pressure regulating systems in renal posttransplantation hypertension. J Hypertens 2004; 22:199-207.
33. Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, Swanson T, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther 2009; 8:856-865.
34. Yang R, Ogasawara AK, Zioncheck TF, Ren Z, He GW, DeGuzman GG, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39:815-820.
35. Chadha PS, Liu L, Rikard-Bell M, Senadheera S, Howitt L, Bertrand RL, et al. Endothelium-dependent vasodilation in human mesenteric artery is primarily mediated by myoendothelial gap junctions intermediate conductance calcium-activated K+ channel and nitric oxide. J Pharmacol Exp Ther 2011; 336:701-708.
36. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, et al. Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in nonclinical species. Cancer Chemother Pharmacol 2009; 64:691-706.
37. Mattson DL, Wu F. Control of arterial blood pressure and renal sodium excretion by nitric oxide synthase in the renal medulla. Acta Physiol Scand 2000; 168:149-154.
38. Mattson DL, Wu F. Nitric oxide synthase activity and isoforms in rat renal vasculature. Hypertension 2000; 35:337-341.
39. Tsikas D, Gutzki FM, Stichtenoth DO. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis. Eur J Clin Pharmacol 2006; 62:51-59.
40. Butler SM, Abrassart JM, Hubbell MC, Adeoye O, Semotiuk A, Williams JM, et al. Contributions of VEGF to age-dependent transmural gradients in contractile protein expression in ovine carotid arteries. Am J Physiol Cell Physiol 2011; 301:C653-C666.
41. Carmines PK, Fallet RW, Che Q, Fujiwara K. Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. Hypertension 2001; 37:569-573.
42. Passmore JC, Fleming JT, Tyagi SC, Falcone JC. Tyrosine kinase receptor alteration of renal vasoconstriction in rats is sex-and agerelated. Can J Physiol Pharmacol 2012; 90:1372-1379.
43. Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, et al. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 2008; 36:905-916.
44. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006; 47: 1075-1083.
45. Meyer-Schwesinger C, Dehde S, Sachs M, Mathey S, Arefi K, Gatzemeier S, et al. Rho-kinase inhibition prevents proteinuria in immunecomplex-mediated antipodocyte nephritis. Am J Physiol Renal Physiol 2012; 303:F1015-F1025.
46. Gong R, Dworkin LD, Brenner BM, Maddox DA. The renal circulations and glomerular ultrafiltration. In: Brenner BM, editor. Brenner and Rector's the kidney. Philadelphia: Saunders Elsevier; 2008. pp. 91-129.
47. Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA. Evaluation of the lithium clearance method: direct analysis of tubular lithium handling by micropuncture. Kidney Int 1995; 47:1023-1030.
48. Leyssac PP, Christensen P. A comparison between endogenous and exogenous lithium clearance in the anaesthetized rat. Acta Physiol Scand 1994; 151:173-179.
49. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nature Med 2009; 15:545-552.
50. Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000; 278:F905-F915.
51. Pavlov TS, Levchenko V, O'Connor PM, Ilatovskaya DV, Palygin O, Mori T, et al. Deficiency of renal cortical EGF increases ENaC activity and contributes to salt-sensitive hypertension. J Am Soc Nephrol 2013; 24:1053-1062.